The global human respiratory syncytial virus (RSV) treatment market is expected to witness significant growth in the coming decade, according to a recent industry report. The market, valued at an estimated US$ 1,533.74 million in 2022, is projected to reach US$ 4,354.93 million by 2032, reflecting a compound annual growth rate (CAGR) of 11%. RSV is a common respiratory …